Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
lines of systematic therapy has been included in the 2024 China National Reimbursement Drug List (NRDL), which will officially take effect on January 1, 2025. (Source: Antengene Corporation Limited press release) The inclusion of XPOVIO's indication in DLBCL by the NRDL is a great news for patients with R/R DLBCL as it will significantly improve the accessibility of this innovative drug, bringing survival benefit to patients at ever lower financial burden on patients and their families. (Source: Prof. Jun Zhu, Peking University affiliated Beijing Cancer Hospital) XPOVIO is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regula
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications [Yahoo! Finance]Yahoo! Finance
- Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsPR Newswire
- Karyopharm Therapeutics Provides Endometrial Cancer Program UpdatePR Newswire
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferencePR Newswire
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Analyst Actions
- 11/1/24 - HC Wainwright
KPTI
Sec Filings
- 12/16/24 - Form DEF
- 12/5/24 - Form PRE
- 12/5/24 - Form 4
- KPTI's page on the SEC website